Hiroyuki Osawa Selected Research

1- (5- (2- fluorophenyl)- 1- (pyridin- 3- ylsulfonyl)- 1H- pyrrol- 3- yl)- N- methylmethanamine

12/2022	Long-term changes in serum gastrin levels during standard dose vonoprazan therapy.
1/2022	Predictors and timing for the development of symptomatic gastroesophageal reflux disease after successful Helicobactor pylori eradication therapy.
3/2021	Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease.
8/2018	Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
12/2017	Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.
9/2017	Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroyuki Osawa Research Topics

Disease

9	Infections 01/2022 - 01/2005
7	Stomach Neoplasms (Stomach Cancer) 05/2022 - 01/2009
7	Neoplasms (Cancer) 01/2022 - 10/2004
6	Gastroesophageal Reflux (GERD) 01/2022 - 01/2003
5	Atrophy 12/2022 - 01/2005
5	Gastritis 02/2011 - 01/2005
3	Fibrosis (Cirrhosis) 01/2022 - 04/2006
3	Pain (Aches) 03/2021 - 01/2016
3	Dyspepsia (Indigestion) 01/2020 - 01/2016
3	Hemorrhage 05/2018 - 12/2004
3	Metaplasia 01/2008 - 01/2002
2	Ulcer 01/2022 - 01/2014
2	Diarrhea 03/2021 - 12/2017
2	Constipation 03/2021 - 12/2017
2	Squamous Cell Neoplasms (Squamous Cell Cancer) 09/2019 - 06/2018
2	Esophagitis 08/2018 - 01/2003
2	Adenocarcinoma 01/2017 - 03/2013
2	Angiodysplasia 01/2014 - 12/2004
2	Neoplasm Metastasis (Metastasis) 03/2013 - 10/2004
2	Body Weight Changes 11/2008 - 10/2006
2	Atrophic Gastritis 11/2008 - 01/2005
2	Inflammation (Inflammations) 06/2008 - 01/2008
1	Polyps 12/2022
1	Diabetes Mellitus 01/2022
1	Chronic Renal Insufficiency 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Esophageal Squamous Cell Carcinoma 09/2019
1	Esophageal Neoplasms (Esophageal Cancer) 09/2019
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2019
1	Epistaxis (Nosebleed) 05/2018
1	Allergic Rhinitis 05/2018
1	Barrett Esophagus (Barrett's Esophagus) 01/2017
1	Peptic Ulcer (Peptic Ulcers) 01/2014
1	Ascites 03/2013
1	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 02/2011
1	Chronic Pancreatitis 01/2007
1	Adenoma (Adenomas) 11/2006
1	Body Weight (Weight, Body) 10/2006
1	Pancreatitis 04/2006
1	von Willebrand Diseases (von Willebrand's Disease) 12/2004
1	Wounds and Injuries (Trauma) 10/2004
1	Pre-Eclampsia (Preeclampsia) 09/2004
1	Acute Disseminated Encephalomyelitis (Postinfectious Encephalomyelitis) 02/2003
1	Transverse Myelitis (Necrotizing Myelitis) 02/2003

Drug/Important Bio-Agent (IBA)

6	1- (5- (2- fluorophenyl)- 1- (pyridin- 3- ylsulfonyl)- 1H- pyrrol- 3- yl)- N- methylmethanamineIBA 12/2022 - 09/2017
4	GhrelinIBA 11/2008 - 01/2005
3	AcidsIBA 12/2022 - 09/2017
3	Proton Pump InhibitorsIBA 01/2022 - 09/2017
3	Z 338IBA 01/2020 - 01/2016
3	AntralIBA 02/2011 - 01/2002
3	Messenger RNA (mRNA)IBA 01/2008 - 01/2002
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2014
2	AnticoagulantsIBA 01/2022 - 05/2018
2	Alkaline PhosphataseIBA 06/2002 - 01/2002
1	GastrinsIBA 12/2022
1	IodineIBA 09/2019
1	Hyaluronic Acid (Hyaluronan)IBA 06/2018
1	PotassiumIBA 12/2017
1	Capsules (Microcapsules)IBA 01/2014
1	IronIBA 02/2011
1	TabletsIBA 02/2011
1	SulfotransferasesIBA 01/2008
1	Galactosylceramides (Galactocerebrosides)IBA 01/2008
1	Sulfoglycosphingolipids (Sulfatides)IBA 01/2008
1	EnzymesIBA 01/2008
1	Proteins (Proteins, Gene)FDA Link 06/2007
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 06/2007
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2007
1	Cadherins (E-Cadherin)IBA 11/2006
1	Dual OxidasesIBA 11/2006
1	Matrix Metalloproteinase 7 (Matrilysin)IBA 11/2006
1	Peptides (Polypeptides)IBA 10/2006
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 09/2006
1	InterleukinsIBA 09/2006
1	CytokinesIBA 09/2006
1	Interleukin-6 (Interleukin 6)IBA 09/2006
1	Fibronectins (Fibronectin)IBA 04/2006
1	CollagenIBA 04/2006
1	Pepsinogen A (Pepsinogen)IBA 01/2005
1	von Willebrand FactorIBA 12/2004
1	Matrix Metalloproteinase 14 (MT1-MMP)IBA 10/2004
1	Matrix Metalloproteinases (MMPs)IBA 10/2004
1	Biological ProductsIBA 10/2004
1	Collagenases (Collagenase)FDA Link 10/2004
1	Tocopherols (Tocopherol)IBA 09/2004
1	ProstaglandinsIBA 09/2004
1	gamma-TocopherolIBA 09/2004
1	IsoprostanesIBA 09/2004
1	gamma-Globulins (gamma-Globulin)IBA 02/2003
1	SteroidsIBA 02/2003
1	RNA (Ribonucleic Acid)IBA 01/2003
1	Oligo-1,6-Glucosidase (Isomaltase)IBA 01/2002
1	DefensinsIBA 01/2002

Therapy/Procedure

10	Therapeutics 12/2022 - 02/2003
7	Lasers (Laser) 06/2021 - 01/2014
3	Endoscopes 05/2022 - 01/2019
1	Renal Dialysis (Hemodialysis) 01/2022
1	Hysterectomy 03/2013
1	Drug Therapy (Chemotherapy) 03/2013
1	Antibiotic Prophylaxis 09/2008